Nidhi Jain, MD
Endocrinology, Diabetes & Metabolism · Little Rock, ARNPI 1306936877
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 479 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations.
Across 479 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Dexcom, Inc.$847
- Stimwave Technologies Incorporated$620
- Abbott$533
- Sanofi-aventis U.S. LLC$502
- Lilly USA, LLC$501
- plus $5K from 34 others
What the payments were for
- Food & beverage$8,748100%
- Education$440%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 91 | $1,134 |
| Dexcom, Inc. | 60 | $847 |
| Stimwave Technologies Incorporated | 5 | $620 |
| Abbott | 30 | $533 |
| Sanofi-aventis U.S. LLC | 35 | $502 |
| Lilly USA, LLC | 28 | $501 |
| Boehringer Ingelheim | 33 | $437 |
| Amgen(2 entities) | 28 | $437 |
| Xeris Pharmaceuticals, Inc. | 13 | $427 |
| Bayer | 26 | $415 |
| AbbVie | 19 | $388 |
| Medtronic(2 entities) | 8 | $378 |
| Insulet Corporation | 22 | $353 |
| Cequr Corporation | 2 | $254 |
| Tandem Diabetes Care, Inc. | 14 | $246 |
| Kyowa Kirin, Inc. | 3 | $197 |
| Corcept Therapeutics | 5 | $105 |
| Nevro Corp. | 6 | $100 |
| Ascendis Pharma Endocrinology Inc | 5 | $89 |
| Recordati_rare_diseases_inc. | 4 | $79 |
| Novartis | 4 | $75 |
| BETA Bionics, Inc. | 5 | $73 |
| AstraZeneca | 5 | $72 |
| Shire North American Group Inc | 4 | $67 |
| Valeritas, Inc. | 2 | $47 |
| Chiesi USA, Inc. | 2 | $43 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| Antares Pharma, Inc. | 2 | $40 |
| Sequel Med Tech, LLC | 2 | $37 |
| Johnson & Johnson | 3 | $36 |
| Radius Health, Inc. | 1 | $32 |
| Averitas Pharma Inc. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Boston Scientific | 1 | $28 |
| BD | 1 | $22 |
| Almatica Pharma LLC | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Lifescan, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$200
- SIMPLERA SENSOR$196
- CRYSVITA$145
- RECORLEV$137
- Wegovy$125
How this compares
$8,792 in reported general payments places this provider in the 60th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
See all endocrinology, diabetes & metabolism providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,539 | $1,655,126 |
| JardianceEmpagliflozin | 760 | $647,063 |
| MounjaroTirzepatide | 505 | $580,766 |
| TrulicityDulaglutide | 162 | $198,604 |
| Tresiba Flextouch U-200Insulin Degludec | 167 | $146,531 |
| Tresiba Flextouch U-100Insulin Degludec | 206 | $134,052 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 264 | $118,921 |
| JanuviaSitagliptin Phosphate | 122 | $112,096 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 796 | $111,339 |
| FarxigaDapagliflozin Propanediol | 82 | $74,029 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 82 | $54,159 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 53 | $49,857 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 70 | $41,650 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $37,976 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $35,684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Rybelsus, Fiasp | $1,134 | $1,694,7781,629 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $501 | $791,128779 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $437 | $666,704786 claims |
| AstraZenecaFarxiga | $72 | $74,02982 claims |
| AbbVieSynthroid | $388 | $21,235300 claims |
| Sanofi-aventis U.S. LLCLantus | $502 | $6,46462 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
Other endocrinology, diabetes & metabolism in Little Rock
- Richard GriffithsLittle Rock$925K
- James ThrasherLittle Rock$349K
- Richard RappLittle Rock$47K
- Shunzhong BaoLittle Rock$40K
- Teresa NimmoLittle Rock$29K
- Madhu BudhrajaLittle Rock$29K
- Joseph HenskeLittle Rock$23K
- Archana JarathiLittle Rock$7K
- Allen ReddingLittle Rock$7K
- Zulekha HamidLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.